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Introduction
Single nucleotide polymorphisms (SNPs) are the most abundant form 
of human genetic variations and a resource for mapping complex genetic 
traits [1,2]. Several efforts, for example the HapMap project, have been made 
to document the frequencies of various SNPs in different ethnic groups and 
human races and to evaluate their associations with diseases [3]. Currently, 
there are no clinical tests to evaluate genetic predisposition to prostate 
cancer risk in men with or without elevated prostate specific antigen (PSA), 
abnormal digital rectal examination (DRE), or both. Reports by Nam et al. 
showed that two SNPs in KLK2 gene: rs2664155 (AA or AG variants) and 
rs198977 (TT or TC variants) were strongly associated with the presence 
of prostate cancer at biopsy [4]. Genome-wide association studies have 
also identified several groups of SNPs (haplotypes) in different genes that 
are linked to prostate cancer risk [5,6]. However, the SNPs in KLK2 gene 
warrant further investigation because the protein product of KLK2 gene 
(hK2) is only secreted by the prostate and its serum levels correlate with 
prostate cancer development [3]. Biologically, the hK2 activates the PSA, 
which is involved in the liquefaction of the seminal fluid thereby aiding 
sperm motility [7].
Objective
The objective of this study was to find out if any of the SNPs in the 
KLK2 gene could predict the presence of prostate cancer at biopsy. The 
second objective was to find out if any associated SNP has a correlation 
with the disease phenotype (tumour grade and/ or pathological grade). 
The third objective was to evaluate the performance of a TaqMan SNP 
genotyping assay for any of the associated SNP and to use the assay 
for genotyping DNA from archived formalin fixed, paraffin-embedded 
(FFPE) tissue sections.
Materials and Methods
Subjects
Sixty consecutive patients who consented to the study (after 
favourable ethical approval by the Bedfordshire Research Ethics 
Committee) were sampled for 5 ml of peripheral blood before they 
had transrectal ultrasound (TRUS) guided prostate biopsy. Most of the 
patients had elevated PSA level (≥ 4.0 ng/ml) and/ or abnormal DRE 
at the time of referral for biopsy. Some patients were referred to the 
clinic due to persistent urinary symptoms. No patient was a known case 
of prostate cancer. The patients were Caucasian whites (British). The 
blood samples were centrifuged at 1840 g for 5 minutes and plasma 
removed for PSA testing. The corpuscular components were lysed in a 
cold red cell lysis buffer (1.55 M Ammonium chloride, 0.01 M EDTA 
and 0.1 M Potassium bicarbonate; adjusted pH 7.4 using 10 M HCl). 
After two washes in the lysis buffer at 10 minutes intervals, white cell 
pellets were finally washed in phosphate buffered saline (PBS) before 
lysis in 1 ml of guanidine isothiocyanate (GITC) buffer. Genomic DNA 
was extracted from 200 μl of the lysates using QiaAmp DNA kit and the 
Qiacube automated extraction system (Qiagen UK).
FFPE Prostate tissue sections
Archived FFPE prostate tissue blocks (n=138) were retrieved from 
the Royal Gloucestershire tissue store following favourable ethical 
approved by the Royal Gloucestershire Research Ethics Committee. 
Two 25 micrometre thick sections were asceptically cut from each tissue 
block and picked into a 2 ml tube. The tubes were briefly centrifuged, 
deparaffinised in two washes of 1 ml xylene for 10 minutes each; the 
xylene decanted and the tissue rehydrated by two washes in 1 ml of 
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100% ethanol before allowing the pellets to dry for 5 minutes on a dry 
heat block kept at 37°C. The tissue pellets were digested overnight in 
540 μl of ATL tissue lysis buffer and 60 μl of proteinase K (Qiagen, UK). 
The digest was centrifuged at 800 g for 5 minutes and the supernatants 
(containing nucleic acids) were collected. A 200 μl of the supernatant 
was used for DNA extraction. Another 300 μl of the supernatant 
was used for RNA extraction; and subsequent complementary DNA 
synthesis using random hexamer priming and the Molony murine 
leukaemic virus reverse transcriptase (M-MLV RT) in a final 50 
μl reaction volume according to manufacturer’s recommendation 
(Promega, UK). The RNA elute was 30 μl and the quality was checked 
by automated electrophoresis using BioRad Experion system. Quality 
of gDNA was checked by the amplification of a 150 bp G6PD from 
each sample using 2 μl of the genomic DNA, 300 nM each of forward 
and reverse primers in a final 20 μl reaction volume using a standard 
polymerase chain reaction (PCR). The primer sequences and thermal 
protocol are available on request.
Direct sequencing
The KLK2 gene was sequenced in four parts covering nearly the 
entire KLK2 gene. The Big Dye X terminator purification system and 
the ABI 3130 genetic analyzer (Applied biosystems) were used for the 
sequencing according the manufacturer’s instructions. The nucleotide 
sequences for primers have been described in details elsewhere [4]. The 
sequences were aligned using the SeqMan component of the DNA star 
software (DNASTAR Inc, USA). The sequences were correlated with 
canonical sequences from the UCSC genome browser (http://genome.
ucsc.edu/) and Entrez SNP database (http://www.ncbi.nlm.nih.gov/).
Allelic discrimination assays
Using the same genomic DNA from blood samples, predesigned 
SNP genotyping assays, based on TaqMan VIC- and FAM- 
fluorescent labelled minor groove binding (MGB) probes for the two 
alleles and specific primers (Applied biosystems, UK) were used in 
genotyping SNPs rs198972 and rs198977: the assay identities were 
C_8705643 and C_736084 respectively. The ABI 7900HT sequence 
detection system (Applied biosystems, UK) was used according to 
manufacturer’s instructions. Genomic DNA from the FFPE tissue 
materials was also genotyped by this method. For each reaction, 50 
to 100 ng (1-2 μl) of sample gDNA was used in setting up the real 
time PCR reaction, for allelic discrimination, in a final 25 μl reaction 
volume using thermal protocol as recommended by the manufacturer 
(Applied Biosystems).
Relative Quantification of KLK2 transcript
The KLK2, G6PD and ABL1 transcripts in the samples were 
measured by a triplex real time PCR in a 20 μl reaction volume using 2 
μl of cDNA, TaqMan gene expression master mix and TaqMan probes 
(FAM for ABL1 and TET for KLK2 using a black hole quencher BHQ 
and CY5 for G6PD with a BHQ). Primer and probe sequences are 
shown in Table 1. The thermal profile was 50°C for 2 minutes, initial 
denaturation at 95°C for 10 minutes; cycle denaturation of 95°C for 15 
seconds, annealing and extension at 60oC for 1 minute for 40 cycles. 
Data was acquired at all stages. The geometric mean of G6PD and 
ABL1 genes were used in normalizing the gene expression of KLK2. The 
normalized relative quantity (NRQ) of KLK2 was calculated using the 
formula NRQ=E Ct KLK2/EGm of Ct ABL and G6PD where E is the PCR efficiency 
for each target, Gm is the geometric mean of Ct values of ABL1 and 
G6PD, the endogenous control genes [8].
Results
Figure 1a shows a representative SYBR safe stain of 2% agarose 
gel of 150 bp G6PD quality control check on gDNA from FFPE tissue 
materials. Figure 1b shows a representative SYBR safe stain of PCR 
products prior to setting up Big Dye terminator reaction. Single intense 
bands yielded good electropherograms during sequencing. Figure 1c 
shows the normalized relative quantity of KLK2 transcript in benign, 
non-involved and prostate cancer cases. KLK2 mRNA (normalized) 
was significantly reduced in the prostate cancer cases compared to BPH 
cases.
Table 2 contains a summary of all the 18 known SNPs identified in 
the KLK2 gene. Eleven SNPs (61%) of the 18 SNPs identified in the 60 
patients’ cohort through direct DNA sequencing had 100% frequency 
of the reference (ancestral) allele in the study population, therefore were 
not investigated further. The remaining 7 SNPs had a heterozygosity 
of 0.07 to 0.40 in the sample population (n=60). Four of them were 
intronic SNPs; three were coding sequence (CDS) SNPs. The CDS 
located SNPs are shown in Figure 2. SNPs rs10422897 and rs198872 
did not show any significant association with any prostate disease (P 
values=0.14 and 0.22 respectively, Chi Square test). The codons in 
both SNPs are for Arginine (R) and Leucine (L) respectively. However, 
the SNP rs198977 had a significant association with prostate cancer 
(P=0.0037, Chi Square test). The T/T allele of the rs198977 occurred 
only in prostate cancer cases. There were 12 prostate cancer cases in the 
60 patients’ cohort (representing 20% cancer detection rate by biopsy 
in this cohort). Four (33%) of the 12 prostate cancer cases had T/T 
allele of rs198977. At the time of sampling their histology status was 
not known. The benign hyperplasia cases were 38 (about 63%) of the 
cohort. Prostatic intraepithelial neoplasia (PIN) was present in 2 cases 
(about 3% of the cohort) and there were 8 non-involved cases (cases of 
chronic inflammation, no dysplasia, no carcinoma; about 13% of the 
cohort).
None of the four intronic SNPs had any significant association 
with prostate cancer (P>0.05, Chi Square test). However, the A/A allele 
of the SNP rs2664155 occurred only in benignhyperplasia patients 
Gene Sequence(5’-3’) Chromosome location Amplicon size
Abelson Forward primer:GATACGAAGGGAGGGTGTACCA
9q34 94bp(ABL1)2 Reverse primer:CTCGGCCAGGGTGTTGAA
 Probe: FAM-GCTTCTGATGGCAAGCTCTACGTCTCCT-TAMRA.
G6PD
Forward primer: GGCGATGCCTTCCATCAG
Xq28 63bpReverse primer: CCAGGTCACCCGATGCA
Probe: CY5-CGGATACACACATATTC-BHQ
KLK2 Forward primer:TGCCCATTGCCTAAAGAAGAATAG 19q13 72bp
 Reverse primer: CCTGTGTCTTCAGGCTCAAACA   
 Probe:Tet-CTGGGTCGGCACAAC-BHQ   
Table 1:  Primer and Probe sets for RQ-PCR (qPCR).
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(5.26% of the BPH cases) as shown in Figure 3. For SNP genotyping 
in the 138 archived FFPE prostate tissue sections, only two SNPs were 
genotyped by the TaqMan allelic discrimination assay (real time PCR 
system). However, there were 100% valid results when the TaqMan 
SNP genotyping was used on the 60 samples that had been previously 
evaluated by direct DNA sequencing. The SNP rs198972 determined 
by TaqMan assay did not show any significant association with any 
prostate disease (P=0.76, Chi Square test). The result was similar to 
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Figure 1: Quality control amplification check for genomic DNA and KLK2 transcript quantification.
(A)Shows a 150 bp G6PD amplified from gDNA from of archived FFPE. All the samples gave good quality genomic DNA. (B) Shows Sybr safe stains of KLK2 PCR 
products of genomic DNA from blood samples. Samples 1 to 5 were 578 bp products (exon 1 of five samples), samples 6 to 10 were 410 bp products (exons 2 of same 
five samples), and samples 11 to 15 were 664 bp products (exon 3+4 of same five samples). The letter L is on the 100bp DNA ladder lane. (C) Normalized relative 
quantity (NRQ) of KLK2 in FFPE prostate tissue materials. N-I stands for non-involved, PCa stands for prostate cancer and BPH for benign nodular hyperplasia. The 
NRQ of KLK2 was significantly reduced in PCa cases (P= 0.001). The horizontal lines (bars) represent median values (the distribution was Non-Gaussian). There 
were 96 cases of prostate cancer, 30 cases of BPH and 12 case of non-involved. The criteria for accepting valid real time PCR results for the KLK2, G6PD and 
ABL1 transcripts were: i) a slope range of -3.30 to -3.60 for the standard curve involving five dilution points (in triplicate at each point), ii) a Y- intercept of ≤ 40, iii) a 
quantification cycle (Cq) difference (Δ Cq) of ≤ 1.0 for a triplicate measurement, iv) a maximum relative fluorescence unit plateau value (RFU value) of ≤ 1  and v) a 
coefficient correlation (R2) of > 0.98 for the standard curve.
Citation: Nna EO, Tothill S, Bailey T (2016) Allelic Variants of KLK2 Gene Predict Presence of Prostate Cancer at Biopsy. J Cancer Diagn 1: 105. 
doi:10.4172/jcd.1000105
Page 4 of 6
Volume 1 • Issue 1 • 1000105
J Cancer Diagn
ISSN: JCD, an open access journal 
previous result on the 60 samples evaluated by resequencing. For the 
rs198977 the T/T allele was also significantly associated with prostate 
cancer, all the T/T genotypes were found only in the prostate cancer 
tissues (4.2% of 96 prostate cancer tissues contained in the 138 archived 
samples). The average heterozygosity of the rs198977 for the sample 
population (British whites) in this study was 0.38.
Overall, there were 7 cases of T/T allele of rs198977 identified in 
this study using direct DNA resequencing and TaqMan SNP genotyping 
assay of 198 samples in total. Two of the seven cases had Gleason score 
8-10; four cases had Gleason Score 6 and one case had Gleason score 
7. There were no low grade cancers (Gleason score 4-5) identified with 
the T/T allele, indicating a possible association with high tumour grade.
Discussion
Of the 18 known SNPs identified in the KLK2 gene through direct 
DNA re-sequencing of 60 patients, only two SNPs showed a significant 
association with prostate diseases. The T/T allele of rs198977 was 
significantly associated with presence of prostate cancer at biopsy. The 
sample size in this study was relatively small. However, in many SNP 
association studies, categories of prostate diseases such BPH, PIN and 
A
B
C
Figure 2: Association of CDS-located SNPs with Prostate diseases.
(A)SNP rs10422897, (B) SNP rs198972 and (C) 198977. All cases of T/T alleles of rs198977 had prostate cancer  and were also associated with high grade tumour.
BPH stands for Benign prostatic hyperplasia
PIN stands for Prostatic Intraepithelial Neoplasia
PCa stands for Prostate Carcinoma
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chronic inflammation are usually all grouped into ‘no tumour category’ 
and are compared with ‘tumour group’. This practice could skew results 
because the detection rate of prostate cancer by histology in a pool of 
patients attending TRUS biopsy is at best 30% [9], and in this cohort 
the cancer detection rate was even lower (20%). There was a higher 
frequency of BPH in prostate lesions. Therefore, larger population 
studies incorporating these sub-groups are necessary to confirm the 
association of SNPs with prostate diseases. Contrary to the report by 
Nam et al., our study showed that the rs2664155 was associated with 
risk of benign hyperplasia rather than prostate cancer. In addition, 
our study showed that the occurrence of T/T allele of rs198977 was 
associated with high tumour grade. Larger studies are still required to 
confirm these associations. This study did not evaluate the association of 
these SNPs in haplotypes. In addition, genotyping SNPs from archived 
tissue samples could be problematic since possible somatic mutations 
were differentiated from germ line variations. 
The normalized quantification of KLK2 showed that the transcript 
level was significantly reduced in prostate cancer cases compared to 
benign cases (P<0.05). Although the protein product of KLK2 is known 
to be increased in prostate cancer progression, our study, in agreement 
with some other studies [10,11], showed that the normalized mRNA 
level was reduced in prostate cancer. It is therefore unclear how the 
KLK2 gene is up-regulated during prostate cancer progression. 
The TaqMan SNP genotyping is a cheap, flexibly high throughput and 
was found suitable for genotyping gDNA from archived paraffin tissue 
materials and blood samples. Both the rs198977 and rs2664155 could 
be determined in the same plate reaction for each patient sample using 
the TaqMan SNP assay. However, known allelic variants (calibrators for 
the three possible variants determined by re-sequencing) must always 
be included in each run for quality control purposes. Again the amount 
of gDNA used in the TaqMan real time PCR for genotyping is very 
important (our optimization assay showed that 50 to 100ng amount of 
gDNA was required for good quality base calling). 
SNPs could provide additional genetic information to help stratify 
patients into risk groups. It might help identify males who will benefit 
from prostate cancer annual screening programmes, which are, in 
many countries, strongly debated [12]. Males who have the T/T allele 
of rs198977, for example, could be enrolled into annual screening 
programme before the age of 50 (the recommended age in some 
countries). SNPs could also inform prognosis, and may help in choice 
of treatment options. For example, if it is confirmed that the T/T allele 
of rs198977 was associated with higher tumour grade, this can influence 
patients with localised prostate cancers to choose a radical treatment 
option earlier on. Although the rs198977 SNP is located in the CDS 
SNP ID Molecular type Genotypes and their frequency (n = 60) Reference allele
rs62113073 intronic C/G (17%) C/C (83%) G/G (0%) C
rs2664155 intronic A/G (37%) G/G (60%) A/A (3%) G
rs2664156 intronic C/T (13%) C/C (77%) T/T (10%) T
rs34652810 5'UTR Del/G (0%) Del/del (100%) G/G (0%) del
rs2070854 intronic A/G (0%) A/A (100%) G/G (0%) A
      
rs198970 intronic A/T (0%) A/A (100%) T/T (0%) A
rs6072 CDS-misense A/C/G (0%) G/G (100%) A/C/G (0%) G
rs61750342 exon C/T (0%) C/C (100%) T/T (0%) C
rs10422897 CDS-misense C/T (7%) C/C (93%) T/T (0%) C
      
rs198972 CDS C/T (40%) C/C (53%) T/T (7%) C
rs1064676 CDS C/T (0%) C/C (100%) T/T (0%) C
rs6070 intronic A/T (40%) T/T (60%) A/A (0%) T
rs6071 intronic A/G (0%) A/A (100%) G/G (0%) A
      
rs1064703 CDS C/T (0%) T/T (100%) C/C (0%) T
rs198977 CDS C/T (37%) C/C (56%) T/T (7%) C
rs60268688 CDS A/C (0%) A/A (100%) C/C (0%) A
rs1059712 CDS A/G (0%) G/G (100%) A/A (0%) G
rs11549921 3'UTR C/T (0%) T/T(100%) C/C (0%) T
Table 2: Frequency distribution of 18 identified SNPs in KLK2 gene.
Note: The SNPs highlighted in yellow showed 100% frequency of the ancestral allele and therefore were not investigated further. UTR stands for untranslated region; CDS 
stands for amino acid coding sequence. The reference allele is the same as ancestral allele.
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Figure 3: Association of rs2664155 (A/A genotype) to Benign Nodular 
Hyperplasia.
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exons of KLK2 gene, the resulting codon is a ‘coding synonymous’, 
which means there is no change in peptide sequence for whichever 
allele of this particular SNP the patient has. It is therefore unclear 
how allelic variation affects the function of the KLK2 gene product. 
The NRQ of the KLK2 gene also showed that it was down regulated in 
prostate cancer cases compared to benign cases.
Conclusion
Two SNPs in the KLK2 gene: rs198977 and rs2664155 were 
significantly associated with prostate cancer risk and benign hyperplasia 
respectively. The T/T allele of rs198977 occurred only in prostate 
cancer cases and was also associated with high tumour grade. The A/A 
allele of rs2664155 was, contrary to previous reports, associated with 
benign nodular hyperplasia. The normalized mRNA level of KLK2 was 
significantly reduced in prostate cancer tissues compared to benign 
cases. The TaqMan SNP genotyping assay provided a cheap and flexibly 
high throughput assay for clinical allelic discrimination in samples 
including gDNA from archived FFPE prostate tissue blocks and blood 
samples.
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